Inamed gets FDA panel date
This article was originally published in The Gray Sheet
Executive Summary
Silicone gel-filled breast implant PMA will go before FDA's General & Plastic Surgery Devices Panel Oct. 14-15. Some patient advocacy groups, including the National Organization for Women, Public Citizen and the National Women's Health Network have raised concerns about Inamed's PMA, filed last December (1"The Gray Sheet, July 28, 2003, p. 10). Inamed's submission is based on data from 1,000 patients followed for at least three years. Competitor Mentor plans to submit its final module, based on two-year data, by year-end...
You may also be interested in...
Anti-Silicone Implant Media Campaign, Rally Planned By Consumer Groups
A petition from Public Citizen appears to have persuaded FDA to disclose the General & Plastic Surgery Devices Panel roster nearly two weeks before the panel's review of a silicone gel breast implant premarket application
Silicone Breast Implant Data Requirements Questioned By Patient Groups
FDA's General & Plastic Surgery Devices Panel will likely consider gel migration and "silent rupture" of silicone breast implants when reviewing Inamed's premarket application
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.